GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Other Current Receivables

Immutep (ASX:IMM) Other Current Receivables : A$5.99 Mil (As of Dec. 2023)


View and export this data going back to 1988. Start your Free Trial

What is Immutep Other Current Receivables?

Immutep's Other Current Receivables for the quarter that ended in Dec. 2023 was A$5.99 Mil.

Immutep's quarterly Other Current Receivables declined from Jun. 2023 (A$7.84 Mil) to Sep. 2023 (A$0.00 Mil) but then increased from Sep. 2023 (A$0.00 Mil) to Dec. 2023 (A$5.99 Mil).

Immutep's annual Other Current Receivables increased from Jun. 2021 (A$6.07 Mil) to Jun. 2022 (A$8.36 Mil) but then declined from Jun. 2022 (A$8.36 Mil) to Jun. 2023 (A$7.84 Mil).


Immutep Other Current Receivables Historical Data

The historical data trend for Immutep's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Other Current Receivables Chart

Immutep Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 3.39 6.07 8.36 7.84

Immutep Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 7.84 - 5.99 -

Immutep Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Immutep Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Immutep's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Immutep (ASX:IMM) Business Description

Industry
Traded in Other Exchanges
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (ASX:IMM) Headlines

No Headlines